Back to Risk Engine

Risk attribution — Raegan Kuphal

v1.0 · cal 2026-05-22

Component breakdown showing every feature that contributed to this patient's risk score.

Computed ≠ stored(J vs I)Open patient detail

Computed score

100

Group J · Stage IV / progressing

Stored A–J score

87

Group I · On treatment

Score buildup

Baseline 5 + +148 positive = 100

BaselineDemographicSymptomComorbidityImagingProcedurePathologyTreatmentFollow-up

Demographic

Subtotal +3
  • Age 50–69

    Most sporadic PDAC presents after age 50.

    Evidence: Current age 50

    +3

Symptom

Subtotal +27
  • Abdominal pain at age ≥ 50

    Unexplained abdominal pain in a patient over 50 warrants pancreas evaluation.

    Evidence: Onset 2024-06-04· Triggers PANDA group C

    +14
  • Jaundice

    Painless jaundice is a hallmark presentation of pancreatic head adenocarcinoma.

    Evidence: Onset 2024-06-24

    +13

Comorbidity

Subtotal +13
  • Has chronic condition(s)

    Chronic disease burden warrants ongoing surveillance.

    Evidence: 7 active conditions

    +13

Imaging

Subtotal +10
  • MRI of abdomen on record

    Imaging suggests the patient has been worked up for pancreatic concern.

    Evidence: MRI on 2024-12-31

    +10

Procedure

Subtotal +42
  • EUS performed

    EUS is the highest-resolution modality for sub-cm pancreatic lesions; performance implies clinical concern.

    Evidence: Endoscopic ultrasonography of pancreas on 2024-10-04· Triggers PANDA group G

    +20
  • Tissue diagnosis procedure

    Biopsy or resection indicates definitive workup or treatment.

    Evidence: EUS-guided fine needle aspiration of pancreas on 2024-10-07

    +22

Pathology

Subtotal +25
  • Pancreatic tumor confirmed

    Confirmed pancreatic malignancy is the defining factor for groups H–J.

    Evidence: Malignant neoplasm of head of pancreas· Triggers PANDA group H

    +25

Treatment

Subtotal +20
  • Active chemotherapy

    Active cytotoxic therapy implies confirmed malignancy with treatment intent.

    Evidence: Oxaliplatin 85 MG/M2 Injection, Irinotecan 180 MG/M2 Injection· Triggers PANDA group I

    +20

Follow-up

Subtotal +8
  • Missed surveillance

    No encounter in over a year increases the chance of unrecognized progression.

    Evidence: Last encounter 3300 days ago

    +8

The Risk Engine computed group (J) is derived purely from the feature contributions above. The stored A–J group (I) comes from the cascade classifier in scripts/classify-risk.ts. Divergence between the two indicates a classifier rule that the scoring weights haven't captured, or vice versa — useful for calibration.